Get the Stockscreener App
95.06
1.08%
1.02
Insmed Inc stock is traded at $95.06, with a volume of 3.10M.
It is up +1.08% in the last 24 hours and down -19.67% over the past month.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
See More
Previous Close:
$94.04
Open:
$93.5
24h Volume:
3.10M
Relative Volume:
1.18
Market Cap:
$20.76B
Revenue:
$819.56M
Net Income/Loss:
$-1.18B
P/E Ratio:
-16.55
EPS:
-5.7434
Net Cash Flow:
$-951.64M
1W Performance:
-1.26%
1M Performance:
-19.67%
6M Performance:
-33.91%
1Y Performance:
-40.63%
1-Day Range:
$0.00
$0.00
1-Week Range:
$93.33
$97.88
52-Week Range:
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
95.06 | 20.76B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
535.17 | 135.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
819.09 | 84.33B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
202.63 | 80.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
875.76 | 55.07B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
382.27 | 43.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-12-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-24-26 | Resumed | Goldman | Buy |
| Jul-21-26 | Initiated | BMO Capital Markets | Outperform |
| Apr-10-26 | Initiated | Raymond James | Outperform |
| Mar-30-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Dec-19-25 | Resumed | Truist | Buy |
| Dec-04-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
The Escalator: CSL, Insmed, Amgen and more - Medical Marketing and Media
Insmed names former Sanofi and Novartis CEO Hudson and biopharma exec Koppikar to board - ROI-NJ
Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Zacks Investment Research
Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Form 4 Insmed Inc: Paul Hudson (Director) For: 19 October By Investing.com - Investing.com Canada
Utpal Koppikar Appointed to Insmed Board, Reports No Ownership of Company Securities - Kalkine Media
Insmed Appoints Two New Directors to Its Board - Insmed Incorporated Investor Relations
Insmed adds two directors with pharma leadership experience - Investing.com
Insmed appoints Paul Hudson and Utpal Koppikar to its Board - TradingView
Insmed adds two independent directors with biopharma backgrounds - StreetInsider
Oral Lung-Disease Tablets: Insmed Brings BRINSUPRI to Japan for NCFB - Trend Hunter
Insmed launches bronchiectasis treatment in Japan By Investing.com - Investing.com Canada
Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan - Yahoo Finance
Insmed IncorporatedLaunches Four Pivotal Phase 3 Studies For TPIP In Pulmonary Diseases - TradingView
Insmed launches four phase 3 trials for lung disease therapy By Investing.com - Investing.com Canada
Three trials have started for Insmed's inhaled treatment; a fourth is expected in the first half of 2027. - Stock Titan
Insmed Incorporated (INSM) Options Chain - Yahoo! Finance Canada
Three presentations will examine an inhaled treatment being studied for high blood pressure in the lungs. - Stock Titan
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $169 to $220 - Moomoo
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), ACADIA Pharmaceuticals (ACAD) and Insmed (INSM) - The Globe and Mail
Insmed Shares Fall After Wolfe Research Downgrade - Yahoo Finance
Wolfe Research Downgrades Insmed to Peer Perform From Outperform - Moomoo
Truist previews biotech earnings with focus on Insmed, BridgeBio By Investing.com - Investing.com Canada
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
BofA cuts Insmed stock price target on valuation concerns By Investing.com - Investing.com India
Weekly Recap: ARIKAYCE sNDA Jan 28, 2027 FDA date and CFO Bonstein exit - TradingView
Wolfe Research Downgrades Insmed to Peer Perform From Outperform - Yahoo Finance
US High Growth Tech Stocks Spotlight Featuring 3 Top Picks - Simply Wall Street
UBS reiterates Insmed stock rating on Brinsupri sales outlook - Investing.com
Does Insmed (INSM) CFO Exit With Reaffirmed Guidance Clarify Or Complicate Its Growth Narrative? - Yahoo Finance
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View - Zacks Investment Research
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View - TradingView
Bonstein to step down as Insmed chief financial officer - ROI-NJ
$100 Invested In Insmed 5 Years Ago Would Be Worth This Much Today - Benzinga
Insmed Announces CFO Transition - Insmed Incorporated Investor Relations
Insmed stock falls as CFO Sara Bonstein to step down - Investing.com
Why is Insmed stock sliding today? By Investing.com - Investing.com India
Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed - Benzinga
Insmed stock falls as CFO Sara Bonstein to step down - Yahoo Finance
Insmed drops as investors weigh CFO departure despite reaffirmed 2026 outlook - Quiver Quantitative
Insmed Incorporated Announces Sara Bonstein Steps Down as Chief Financial Officer, Effective October 30, 2026 - marketscreener.com
Insmed Incorporated Reaffirms Earnings Guidance for the Full-Year 2026 - marketscreener.com
Insmed Q2 2026 Earnings Call Transcript - Benzinga
Insmed CFO Sara Bonstein to step down, reaffirms guidance - TradingView
Insmed CFO Sara Bonstein to step down on October 30 By Investing.com - Investing.com Canada
Insmed CFO Sara Bonstein to step down Oct 30; c... - pluang.com
Insmed CFO Sara Bonstein to Separate, Search Underway for Successor - TradingView
Insmed (INSM) Announces CFO Transition - TradingView
Insmed Announces CFO Transition - Yahoo Finance
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Insmed Inc Stock (INSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Brennan David R | Director |
Sep 09 '26 |
Proposed Sale |
123.99 |
25,000 |
3,099,729 |
0 |
| SHAROKY MELVIN MD | Director |
Aug 17 '26 |
Sale |
127.53 |
5,000 |
637,650 |
0 |
| MELVIN SHAROKY | Director |
Aug 17 '26 |
Proposed Sale |
127.53 |
5,000 |
637,637 |
0 |
| Roger Adsett | Officer |
Aug 10 '26 |
Proposed Sale |
133.26 |
239,850 |
31,963,198 |
0 |
| Adsett Roger | Chief Operating Officer |
Aug 10 '26 |
Option Exercise |
20.45 |
239,850 |
4,905,570 |
338,594 |
| Adsett Roger | Chief Operating Officer |
Aug 10 '26 |
Sale |
133.27 |
239,850 |
31,964,810 |
98,744 |
| Martina Flammer | Officer |
Aug 06 '26 |
Proposed Sale |
128.61 |
27,173 |
3,494,755 |
0 |
| Flammer Martina M.D. | Chief Medical Officer |
Aug 06 '26 |
Option Exercise |
21.20 |
27,173 |
576,126 |
87,659 |
| Flammer Martina M.D. | Chief Medical Officer |
Aug 06 '26 |
Sale |
128.61 |
27,173 |
3,494,838 |
60,486 |
| Lewis William | Chair and CEO |
Jul 23 '26 |
Sale |
106.06 |
10,700 |
1,134,890 |
259,058 |
1.77%
3.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):